Head of Dermatology and Laser Department, College of Medicine, University of Kufa, Najaf, Iraq.
Department of Dermatology, University of Babylon College of Medicine, Babylon, Iraq.
Skin Res Technol. 2023 Aug;29(8):e13442. doi: 10.1111/srt.13442.
The human papillomavirus that causes warts is usually harmless, and it can infect any part of the skin or mucous membranes. Despite the availability of several treatments, warts often return, and scarring, pigmentation changes, and recurrence are all possible side effects.
Intralesional vitamin D3 was employed as an immunotherapy for cutaneous warts in the current investigation.
In Al-Sadr Medical City in the city of Al-Najaf Al-Ashraf, a skin clinic conducted a therapeutic clinical experiment. A total of 204 cutaneous warts were examined in 40 patients (14 men and 26 females). Vitamin D3 solution of the dose (600 000 IU) was injected into the lesions' bases, with 0.2 mL per patient. Each session could only inject up to five warts. The injections were given every 2 weeks for a total of four times. Instructing patients to forego the use of any topical or oral medication was also a part of the protocol. Each patient was evaluated for recurrence risk before each therapy and then again 6 months later.
There was a wide range of patient ages in this study, from 20 months to 52 years. About 65% of the cases included females. When looking at the many kinds of warts, the most prevalent was the common wart (71.6%). After four treatments, a positive response was considered to have occurred when all lesions had disappeared, a partial response when more than half of the lesions had disappeared, and no reaction when less than half of the lesions had disappeared. The final tally was 81.9% for those who responded in whole, 11.3% for those who responded partially, and 6.9% for those who did not respond at all. Next-session complete response rates were 12.7%, 29.9%, 54.9%, and 81.9%, respectively. Thirteen people experienced adverse symptoms, most noticeably minor swelling and itching. Within 6 months of follow-up, warts had completely disappeared for all patients with a partial or modest response except one who had no reaction.
Vitamin D3 administered intralesional is an effective and low-cost treatment for cutaneous warts.
引起疣的人类乳头瘤病毒通常是无害的，它可以感染皮肤或粘膜的任何部位。尽管有几种治疗方法，但疣经常复发，瘢痕形成、色素改变和复发都是可能的副作用。
本研究采用局部维生素 D3 作为皮肤疣的免疫疗法。
在纳杰夫市的萨德尔医疗城的一家皮肤科诊所进行了一项治疗性临床试验。对 40 名患者（14 名男性和 26 名女性）的 204 个皮肤疣进行了检查。将剂量为 60 万 IU 的维生素 D3 溶液注入病变基底，每位患者注射 0.2 毫升。每次治疗最多只能注射 5 个疣。每 2 周注射一次，共 4 次。方案还包括指导患者避免使用任何局部或口服药物。每位患者在每次治疗前和 6 个月后都要评估复发风险。
本研究患者年龄范围广泛，从 20 个月至 52 岁。大约 65%的病例为女性。在观察多种疣时，最常见的是寻常疣（71.6%）。经过四次治疗，如果所有病变均消失，则认为出现了阳性反应，如果超过一半的病变消失，则认为出现了部分反应，如果不到一半的病变消失，则认为没有反应。完全反应的总比例为 81.9%，部分反应的比例为 11.3%，完全无反应的比例为 6.9%。下一次治疗的完全反应率分别为 12.7%、29.9%、54.9%和 81.9%。13 人出现不良反应，最明显的是轻微肿胀和瘙痒。在 6 个月的随访中，除了 1 名无反应者外，所有部分或中度反应者的疣均完全消失。
局部给予维生素 D3 是一种有效且低成本的皮肤疣治疗方法。
